Targovax ASA: Registration of share capital increase following exercise of employee options and settlement of restricted stock units
February 24, 2017 12:18 ET
|
Targovax ASA
Reference is made to the stock exchange notice of 10 February 2017 regarding the board of directors' resolution to increase the share capital in Targovax ASA (the "Company") in connection with the...
Targovax ASA: Exercise of employee share options and restricted stock units in Targovax ASA
February 24, 2017 05:29 ET
|
Targovax ASA
Reference is made to the stock exchange notice of 10 February 2017 regarding increase of the share capital in Targovax ASA (the "Company") relating to exercise of employee options and settlement of...
Targovax ASA: Fourth quarter and full year 2016 results
February 16, 2017 01:01 ET
|
Targovax ASA
Oslo, Norway, 16 February 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces...
Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of restricted stock units
February 13, 2017 09:53 ET
|
Targovax ASA
Lars Lund-Roland, board member of Targovax ASA, has on 13 February 2017 subscribed 4,417 shares in Targovax ASA at a price of NOK 0.10 per share in connection with settlement of vested restricted...
Targovax ASA: Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units
February 10, 2017 03:21 ET
|
Targovax ASA
The board of directors of Targovax ASA (the "Company"), has on 9 February 2017, in accordance with the authorisations granted by the general meeting 13 April 2016, resolved: to increase the share...
Targovax ASA: Invitation to fourth quarter and full year 2016 results presentation Thursday 16 February
February 06, 2017 01:00 ET
|
Targovax ASA
Oslo, Norway, 6 February 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its fourth quarter and full...
Targovax announces encouraging top line two-year survival data from TG01 clinical trial in resected pancreatic cancer patients
February 02, 2017 04:44 ET
|
Targovax ASA
Survival rate of 68% from first patient cohort vs published historical rate of 30-53% suggests signal of clinical efficacy for the drug candidate Full data set from first patient cohort to be...
Targovax announces appointment of Erik Digman Wiklund as CFO
January 05, 2017 01:13 ET
|
Targovax ASA
Oslo, Norway, 5 January 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that...
Targovax to present at DNB healthcare conference
December 13, 2016 01:06 ET
|
Targovax ASA
Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, announces that...
Targovax ASA: Grant of share options
December 09, 2016 15:15 ET
|
Targovax ASA
Oslo, Norway, 9 December 2016: The Board of Directors of Targovax ASA (the "Company") has resolved to grant 420,000 options to subscribe for shares in the Company to employees under the Company's...